Nubratori RX is a Section 503B FDA Registered Outsourcing Facility (OSF). Nubratori RX began in 2014 as a challenge to the founder, CEO, and Pharmacist, Robert P Nickell, to create the best FDA regulated drug compounding and manufacturing facility in the USA.  

 

Nubratori RX is located in Southern California and currently exists in close to 15000 square feet of non-sterile and sterile lab space, with expansion plans for doubling by the summer of 2025. Nubratori RX follows FDA Guidelines for current Good Manufacturing Practice (cGMP) and provides compounded sterile injectables and non-sterile topical creams, solutions, and capsules.  Nubratori RX is currently licensed to ship in 45 states plus Washington DC, with plans for all 50 by end of 2023.

 

Under the guidance of the FDA, Outsourcing Facility products are non-patient specific, shipped across state lines, and sold to licensed Healthcare Providers for Office Use including hospitals, physicians, clinics, and pharmacies. This allows patients to obtain clinically significant and necessary medications, as ordered by their providers.

 

Outsourcing Facility medications are the only class of FDA Registered Facilities that are exempt from the new drug approval process.

​

Medications produced at Nubratori RX, including sterile and non-sterile finished products are listed under the US Food and Drug Administration Structured Product Listing Marketing Category: 

 

Outsourcing Facility Compounded Human Drug Product (Exempt From Approval Requirements)        

 

Nubratori RX is a proud member of the Outsourcing Facility Association, and the Alliance for Pharmacy Compounding.